28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy Download PDF Post navigationPreviousPrevious post:AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankNextNext post:AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)Related PostsAB Science webcast – Microtubule Destabilizer Agents (MDA) platformMarch 16, 2023AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CETMarch 15, 2023AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)March 13, 2023AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankJanuary 31, 2023
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CETMarch 15, 2023
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)March 13, 2023
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankJanuary 31, 2023
